Cyclosporin but not tacrolimus significantly increases salivary cytokine contents in rats

Journal of Periodontology

Volumn 76, Issue 9, 2005, Pages 1520-1525

  Spolidorio, Luís Carlos ^a   Holzhausen, Marinella ^a   Palomari Spolidorio, Denise M ^a   Nassar, Carlos A ^a   Nassar, Patricia O ^a   Muscará, Marcelo Nicolás ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal studies; Cyclosporin A adverse effects; Gingival hyperplasia etiology; Growth factors, epidermal; Growth factors, tumor 1; Interleukin 6; Saliva analysis; Tacrolimus adverse effects

Indexed keywords

CYCLOSPORIN; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONNECTIVE TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GINGIVA OVERGROWTH; HISTOMETRY; MALE; MOLAR TOOTH; MOUTH MUCOSA; NONHUMAN; RAT; SALIVATION;

ANIMALS; CYCLOSPORINE; CYTOKINES; EPIDERMAL GROWTH FACTOR; GINGIVAL OVERGROWTH; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; RATS; RATS, SPRAGUE-DAWLEY; SALIVA; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 26944464177     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.9.1520     Document Type: Article

References (53)

1. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003;14:617-630.
2. Kirk AD. What's new-what's hot in basic science: American Transplant Congress 2004. Am J Transplant 2004;4:1741-1746.
3. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-975.
4. Ersoy A, Ersoy C, Tekce H, Yavascaoglu I, Dilek K. Diabetic ketoacidosis following development of de novo diabetes in renal transplant recipient associated with tacrolimus. Transplant Proc 2004;36:1407-1410.
5. Arne-Bes MC. Neurotoxic effects of medications: An update. Rev Med Liege 2004;59:118-123.
6. Bayes B, Lauzurica R, Granada ML, et al. Diponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 2004;15:26-30.
7. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-653.
8. Martins L, Ventura A, Branco A, et al. Cyclosporine versus tacrolimus in kidney transplantation: Are there differences in nephrotoxicity? Transplant Proc 2004;36:877-879.
9. Prasad GV, Nash MM, McFarlane PA, Zaltzman JSA. Numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors. Nephron Clin Pract 2004;9:35-40.
10. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004;75:434-447.
11. Spolidorio LC, Spolidorio DM, Holzhausen M. Effects of long-term cyclosporin therapy on the periodontium of rats. J Periodontal Res 2004;39:257-262.
12. Ellis JS, Seymour RA, Taylor JJ, Thomason JM. Prevalence of gingival overgrowth in transplant patients immunosuppressed with tacrolimus. J Clin Periodontol 2004;31:126-131.
13. Hernandez G, Arriba L, Frias MC, et al. Conversion from cyclosporin A to tacrolimus as a non-surgical alternative to reduce gingival enlargement: A preliminary case series. J Periodontol 2003;74:1816-1823.
14. Radwan-Oczko M, Boratynska M, Klinger M, Zietek M. Risk factors of gingival overgrowth in kidney transplant recipients treated with cyclosporine. A. Ann Transplant 2003;8:57-62.
15. Ruhl S, Hamberger S, Betz R, Sukkar T, et al. Salivary proteins and cytokines in drug-induced gingival overgrowth. J Dent Res 2004;83:322-326.
16. Al Nowaiser A, Lucas VS, Wilson M, Roberts GJ, Trompeter RS. Oral health and caries related microflora in children during the first three months following renal transplantation. Int J Paediatr Dent 2004;14:118-126.
17. Markopoulos AK, Belazi M, Drakoulakos D, et al. Epidermal growth factor in saliva and serum of patients with cyclosporin-induced gingival overgrowth. J Periodontal Res 2001;36:88-91.
18. Cotrim P, de Andrade CR, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD. Expression of matrix metalloproteinases in cyclosporin-treated gingival fibroblasts is regulated by transforming growth factor (TGF)-beta1 autocrine stimulation J Periodontol 2002;73:1313-1322.
19. Gabryel B, Labuzek K, Malecki A, Herman ZS. Immunophilin ligands decrease release of pro-inflammatory cytokines (IL-1beta, TNF-alpha and IL-2 in rat astrocyte cultures exposed to simulated ischemia in vitro. Pol J Pharmacol 2004;56:129-136.
20. Kovacs EJ. Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 1991;12:17-23.
21. Coletta RD, Reynolds MA, Martelli-Junior H, Graner E, Almeida OP, Sauk JJ. Testosterone stimulates proliferation and inhibits interleukin-6 production of normal and hereditary gingival fibromatosis fibroblasts. Oral Microbiol Immunol 2002;17:186-192.
22. Johnson S, Qi S, Xu D, et al. Synergistic effects of RAD and Neoral in inhibition of host-vs.-graft and graft-vs.-host immune responses in rat small-bowel transplantation. Microsurgery 2003;23:476-482.
23. Araujo CS, Graner E, Almeida OP, Sauk JJ, Coletta RD. Histomorphometric characteristics and expression of epidermal growth factor and its receptor by epithelial cells of normal gingiva and hereditary gingival fibromatosis. J Periodontal Res 2003;38:237-241.
24. Kagami H, Hiramatsu Y, Hishida S, et al. Salivary growth factors in health and disease. Adv Dent Res 2000;14:99-102.
25. Jiang H, Takahara S, Takano Y, et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. Transplant Proc 1991;23:540-541.
26. Jiang H, Fujitsu T, Sakuma S, et al. Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine. Transplant Proc 1995;27:367-369.
27. Fischer RG, Klinge B. Clinical and histological evaluation of ligature-induced periodontal breakdown in domestic ferrets immunosuppressed by cyclosporin-A. J Clin Periodontol 1994;21:240-249.
28. Wright HJ, Chapple IL, Blair F, Matthews JB. Crevicular fluid levels of TGF beta1 in drug-induced gingival overgrowth. Arch Oral Biol 2004;49:421-425.
29. James JA, Jamal S, Hull PS. Tacrolimus is not associated with gingival overgrowth in renal transplant patients. J Clin Periodontol 2001;28:848-852.
30. Morisaki I, Fukui N, Fujimori Y, Murakami J, Daikoku H, Amano A. Effects of combined oral treatments with cyclosporine A and nifedipine or diltiazem on drug-induced gingival overgrowth in rats. J Periodontol 2000;71:438-443.
31. Spolidorio LC, Merzel J, Villalba H, Vargas PA, Coletta RD, Almeida OP. Morphometric evaluation of gingival overgrowth and regression caused by cyclosporin in rats. J Periodontal Res 2001;36:384-389.
32. Kataoka M, Seto H, Wada C, Kido J, Nagata T. Decreased expression of alpha 2 integrin in fibroblasts isolated from cyclosporin A- induced gingival overgrowth in rats. J Periodontal Res 2003;38:533-537.
33. Chang HL, Fu E, Nieh S, Wang SL. Gingival overgrowth induced by different dosages of cyclosporin in rats. Zhonghua Yi Xue Za Zhi 1995;55:290-295.
34. Nishikawa S, Nagata T, Morisaki I, Oka T, Ishida H. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model J Periodontol 1996;67:463-471.
35. Ueno T, Kagawa T, Kanou M, et al. Pathological change of articular cartilage in the mandibular head treated with immunosuppressant FK 506. Histol Histopathol 2004; 19:15-21.
36. Fukunaga J, Sugahara T. Osteoporosis induced by immunosuppressant. Nippon Rinsho 2004;62:740-743.
37. Torres A, Garcia S, Barrios Y, Hernandez D, Lorenzo V. Bone metabolism alterations after kidney transplantation. Nefrologia 2003;23:122-126.
38. Linden GJ, Haworth SE, Maxwell AP, et al. The influence of transforming growth factor-beta1 gene polymorphisms on the severity of gingival overgrowth associated with concomitant use of cyclosporin A and a calcium channel blocker. J Periodontol 2001;72:808-814.
39. Martelli-Junior H, Cotrim P, Graner E, Sauk JJ, Coletta RD. Effect of transforming growth factor-beta1, interleukin-6, and interferon-gamma on the expression of type I collagen, heat shock protein 47, matrix metalloproteinase (MMP)-1 and MMP-2 by fibroblasts from normal gingiva and hereditary gingival fibromatosis. J Periodontol 2003;74:296-306.
40. Das SJ, Newman HN, Olsen I. Keratinocyte growth factor receptor is upregulated in cyclosporin A-induced gingival hyperplasia. J Dent Res 2002;81:683-687.
41. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996;80:40-45.
42. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: A complex problem. Cytokine Growth Factor Rev 2000;11:133-145.
43. Coupes BM, Williams S, Roberts IS, Short CD, Brenchley PE. Plasma transforming growth factor beta(1) and platelet activation: Implications for studies in transplant recipients. Nephrol Dial Transplant 2001;16:361-367.
44. Stabellini G, Carinci F, Luigi Bedani P. Cyclosporin A and transforming growth factor beta modify the pattern of extracellular glycosaminoglycans without causing cytoskeletal changes in human gingival fibroblasts. Transplantation 2002;73:1676-1679.
45. Coletta RD, Almeida OP, Reynolds MA, Sauk JJ. Alteration in expression of MMP-1 and MMP-2 but not TIMP-1 and TIMP-2 in hereditary gingival fibromatosis is mediated by TGF-beta 1 autocrine stimulation. J Periodontal Res 1999;34:457-463.
46. Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000;58:1174-1185.
47. Sarosiek J, Bilski J, Murty VL, Slomiany A, Slomiany BL. Role of salivary epidermal growth factor in the maintenance of physicochemical characteristics of oral and gastric mucosal mucus coat. Biochem Biophys Res Commun 1988;152:1421-1427.
48. Sarosiek J, Feng T, McCallum RW. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci 1991;302:359-363.
49. Modeer T, Andersson G. Regulation of epidermal growth factor receptor metabolism in gingival fibroblasts by phenytoin in vitro. J Oral Pathol Med 1990;19:188-191.
50. Ershler WB, Sun WH, Binkley N. The role of interleukin-6 in certain age-related diseases. Drugs Aging 1994;5:358-365.
51. Kurtis B, Develioglu H, Taner IL, Balos K, Tekin IO. IL-6 levels in gingival crevicular fluid (GCF) from patients with non-insulin dependent diabetes mellitus (NIDDM), adult periodontitis and healthy subjects. J Oral Sci 1999;41:163-167.
52. Williamson MS, Miller EK, Plemons J, Rees T, Iacopino AM. Cyclosporine A upregulates interleukin-6 gene expression in human gingiva: Possible mechanism for gingival overgrowth. J Periodontol 1994;65:895-903.
53. Eickelberg O, Kohler E, Reichenberger F, et al. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J Physiol 1999;276:814-824.